jpg.jpg
First Patient Treated in Phase 1 Clinical Trial Of Incysus Therapeutics Gamma Delta (γδ) T Cell Immunotherapy for Patients With Newly Diagnosed Glioblastoma
02 juin 2020 07h00 HE | Incysus Therapeutics, Inc.
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
vyriad logo.jpg
Vyriad Inc. to Present Clinical Trial Updates for its Oncolytic Virotherapies at Virtual 2020 ASCO Annual Meeting
29 mai 2020 07h30 HE | Vyriad
ROCHESTER, Minn., May 29, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced today that it will present data and information about the design of clinical trials evaluating its oncolytic viruses at the...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
27 mai 2020 06h45 HE | Zynerba Pharmaceuticals, Inc.
- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist - - Safety Data Reinforce...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
26 mai 2020 08h30 HE | Aeglea BioTherapeutics, Inc.
  Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine Favorable Safety Profile, Consistent with...
Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
22 mai 2020 09h00 HE | Samumed, LLC.
SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates...
Surface Logo New Version-color.png
Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
20 mai 2020 07h05 HE | Surface Oncology, Inc.
CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
logo.jpg
HalioDx's expertise applied to ImCheck’s EVICTION Trial
19 mai 2020 07h50 HE | HalioDx
HalioDx to Characterize the Immune Contexture ofPatients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial HalioDx’s immunoscoring technologies  to characterize patients treated with ImCheck’s...
LogoPressRelease.jpg
Fluidigm to Present at Upcoming Health Care Investor Conferences
13 mai 2020 16h02 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
TuftsCSDD-Logo-Color.jpg
Tufts Center for the Study of Drug Development Establishes Demographic Benchmarks for Pivotal Clinical Trials, Showing Areas of Under-Representation
12 mai 2020 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, May 12, 2020 (GLOBE NEWSWIRE) -- Although up to 90% of pivotal clinical trials for drugs approved for sale in the United States provide data on study participants by sex, race, and age, less...
LogoPressRelease.jpg
Fluidigm Announces First Quarter 2020 Financial Results
07 mai 2020 16h05 HE | Fluidigm Corporation
First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for...